Brief: Ondine Biomedical Says Lantern Trial Meets Primary Efficacy Endpoint
01/09/2026 08:21
BRIEF-Ondine Biomedical Says Lantern Trial Meets Primary Efficacy Endpoint Sept 1 (Reuters) - Ondine Biomedical Inc OBI.L:
ONDINE BIOMEDICAL - POSITIVE TOPLINE RESULTS IN US PHASE 3 STUDY
ONDINE BIOMEDICAL - LANTERN TRIAL MEETS PRIMARY EFFICACY ENDPOINT
ONDINE BIOMEDICAL - NO TREATMENT-RELATED SERIOUS SAFETY CONCERNS IDENTIFIED IN TOPLINE REVIEW
ONDINE BIOMEDICAL - TO ENGAGE FDA IN PRE-NEW DRUG APPLICATION PROCESS
Source text: ID:nRSA8542Sa
Further company coverage: OBI.L
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Ondine Biomedical
See all newsAIM Ondine Biomedical - Capital Access Window - Ondine Biomedical Inc
Brief: Ondine Biomedical Confirms Total Gross Proceeds From Placing And Subscription Are £10 Million
Ondine Biomedical - Result of Fundraise, Restoration of Trading & TVR
Brief: Ondine Biomedical Announces A Proposed Fundraising Of About £10 Mln
Ondine Biomedical - Proposed c.£10m (C$18.88m) Fundraise